The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and
the support of male sexual-related functions, as well as in the progression of prostate …

Two novel oral drugs that target androgen signaling have recently become available for the
treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate …

Chondrosarcoma is the second most common malignant bone tumor. It is characterized by
low vascularity and an abundant extracellular matrix, which confer these tumors resistance …

Androgen receptor (AR) signaling is a key pathway in prostate cancer, and patients are
initially treated with androgen deprivation therapy. Patients who have stopped responding to …

Objectives The objective of the study is to compare the efficacy and safety of alternative
androgen therapy (AAT) with enzalutamide+ androgen deprivation therapy (ADT) and …

Objective To review the efficacy and safety of low-dose versus standard-dose enzalutamide,
apalutamide or darolutamide treatment for metastatic prostate cancer. Methods and analysis …

Objective This project aims to identify the top 30 drugs most commonly associated with
constipation and their signal values within the FDA Adverse Event Reporting System …

Purpose We conducted preclinical experiments and phase I clinical trial to investigate the
safety, pharmacokinetics (PK) and antitumour effects of GT0918 in castration-resistant …

Background The purpose of the study is to evaluate real-world effectiveness and safety of
enzalutamide in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) in …

Background/Aim: It has been reported that some adverse events (AEs) of enzalutamide
(ENZ) occur more frequently in Japanese patients with castration-resistant prostate cancer …